VPRIV® (velaglucerase alfa) for injection is a prescription medication indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.

laura’s story

AGE: 20s

Age at Diagnosis: 12

Location: Puerto Rico

Laura’s story is a testament to hope and perseverance. Growing up with type 1 Gaucher disease (GD1) was challenging, not least because she rarely met others who shared her experience. However, she finds joy in connecting with younger patients now, offering them the wisdom and support she wished she had received.

0:00

listen to Laura’s story

Discover Laura’s story below, or click play to hear
it in her own words.

Play Icon
Picture of Laura as a child

Challenges of Childhood

“For a long time, my teachers did not understand me or what I was going through, and I had to deal with a lot of bullying. It was difficult to run, jump, skip, or keep up with the other kids.”

From a young age, Laura faced numerous health struggles. At just four years old, she contracted dengue fever, which was initially misdiagnosed as Epstein–Barr virus. However, her mother later noticed other symptoms and suspected something more was at play. Following recommendations from family, she was taken to specialists, eventually being diagnosed with splenomegaly and thrombocytopenia. Two years later, at the age of seven, she received another diagnosis—rheumatoid arthritis. Despite visits to hematologists and rheumatologists, her condition remained a mystery, with doctors offering diagnoses they were familiar with, but none that fully explained her symptoms.

Laura’s childhood was filled with countless medical tests, from MRIs to bone marrow biopsies. For years, doctors suspected conditions like lupus or cancer, but nothing seemed to fit. Throughout this uncertain time, Laura struggled not only with her health but also with social challenges. Frequent hospital visits meant missing school, which led to misunderstandings with teachers and bullying from classmates. Her swollen left side, a result of her enlarged spleen, made her a target, and she often felt isolated.

Finding Support in Facing Diagnosis

“My mom…helped me manage my new diagnosis. She sat me down one night in the living room and said: ‘This is what you have to deal with. But just so you know, you’re not alone. You have me and your father, and that’s all that matters.”

At age 12, after a particularly difficult period involving severe knee inflammation, her rheumatologist consulted a geneticist. This crucial step finally led to the correct diagnosis: GD1.

While receiving the diagnosis was a relief, it also brought new worries and challenges. Living in Puerto Rico, accessing treatment was not straightforward, and it took a year to find the right hospital. At one point, her family even considered relocating to improve her access to care.

watch Love, Me Video

Laura Love, Me video

Laura’s mother played a vital role in helping her come to terms with the diagnosis. Sitting her down one night, she reassured Laura that she was not alone, reminding her that their family would face this challenge together. A children’s book titled ‘David Explores Gaucher Disease’ also helped Laura understand her condition in a relatable way.

Laura as a young girl

Starting Treatment and Adjusting to Life

“The advice I have for those about to start infusion is not to be scared of change. To give yourself a try … You will discover a lot about yourself you didn’t know before.”

After thorough discussions with her family and doctors, carefully considering the risks and benefits of the available treatment options, a decision was made for Laura to begin enzyme replacement therapy with VPRIV. Her doctors explained that VPRIV is intended for the long-term treatment of GD1 and provided detailed information about its potential side effects.

Every patient’s treatment experience will be different. Her progress was closely monitored by her doctors, and they were pleased with improvements in her hemoglobin levels, platelet counts, and spleen size. Treatment days became a part of her routine, starting early in the morning and involving hospital visits, infusions, and check-ins with her doctors. While she doesn’t always feel like going, Laura values the relationships she’s built with her healthcare team, seeing them as an extended family.

Growing and Looking Forward

“I want to become a community social worker. I want to continue with my activism in my community and all over Puerto Rico. I want to continue treatment and continue sharing my story outside of Puerto Rico.”

Laura’s experience with managing her GD1 hasn’t been without challenges, and some are unavoidable. When Hurricane Maria brought devastation to Puerto Rico, it cut power to the hospitals, resulting causing delay to her treatment. Thankfully, though, such disruptions rare and Laura remains committed to maintaining her consistent treatment plan.

Today, Laura is a university student majoring in social work, an active community leader, and an advocate for others living with Gaucher disease. She is especially passionate about sharing the struggles she’s faced as a woman from the small-town community Barrio Obrero Marine and how that impacts her life with GD1 and her access to treatment. She finds fulfillment in sharing her story as a VPRIV ambassador, building connections, and helping stop others from feeling alone.

Laura as an adult

Reflecting on her journey, Laura emphasizes the importance of support systems, managing energy levels, and seeking spiritual grounding. She encourages others with Gaucher disease to seek out communities that understand their experiences and to take things step by step.

If there’s one word that encapsulates Laura’s journey, it’s resilience. She has faced numerous challenges, but her determination to live life to the fullest remains unwavering. Her story serves as an inspiration to others, proving that with the right support, management, and mindset, life with Gaucher disease can still be meaningful and fulfilling.

important safety information <

Life-threatening hypersensitivity reactions, including anaphylaxis may occur with VPRIV treatment. This reaction may occur early in treatment or after many doses. Seek immediate help if you experience wheezing, shortness of breath, trouble breathing, itching, hives, rapid heartbeat, swelling of the tongue or throat.

important safety information <

Life-threatening hypersensitivity reactions, including anaphylaxis may occur with VPRIV treatment. This reaction may occur early in treatment or after many doses. Seek immediate help if you experience wheezing, shortness of breath, trouble breathing, itching, hives, rapid heartbeat, swelling of the tongue or throat. VPRIV should be administered under the supervision of a healthcare professional. Appropriate medical support should be available when VPRIV is administered.

Hypersensitivity reactions were the most commonly observed side effects in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of hypersensitivity reactions were: headache, dizziness, low blood pressure, high blood pressure, nausea, tiredness/weakness, and fever. Hypersensitivity reactions in the clinical trials include any event considered related to and occurring within up to 24 hours of VPRIV infusion, including one case of anaphylaxis. Generally the reactions were mild and, in patients not previously treated, occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. After the drug was approved, additional hypersensitivity reactions of chest discomfort, difficulty breathing, itching and vomiting have been reported. In some cases, vomiting can be serious and require hospitalization and/or stopping the medication.

If anaphylactic or other acute reactions occur, seek immediate medical care. Your healthcare provider will immediately discontinue the infusion of VPRIV and initiate the appropriate medical treatment. A hypersensitivity reaction should be treated based on the severity of the reaction. Your healthcare provider may manage a reaction by slowing the infusion rate or treating with medicine such as antihistamines, fever-reducing agents and/or corticosteroids or possibly stopping the medication and then restarting with a longer infusion time. For patients who have had symptoms of hypersensitivity reaction to enzyme replacement therapy, the doctor may consider treating the patient with antihistamines and/or corticosteroids before an infusion to help prevent such a reaction from happening.

The most commonly reported side effects during clinical studies (in ≥10% of patients) were hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, increased time it takes for blood to clot, tiredness/weakness, and fever. In clinical studies, the overall frequency of side effects was generally higher in the patients not previously treated with ERT than in the patients who switched from imiglucerase to VPRIV.

Talk to your doctor if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

The safety and efficacy profiles were similar in pediatric (ages 4 to 17) and adult patients. The safety of VPRIV has not been established in patients under 4 years of age. Side effects more commonly seen in pediatric patients compared to adult patients include (>10% difference): rash, increased time it takes for blood to clot, and fever.

The side effect profile in elderly patients was generally similar to that seen in pediatric and other adult patients. In general, dose selection for an elderly patient should be approached cautiously, considering other existing medical conditions.

As with all therapeutic proteins, there is a potential for developing antibodies to VPRIV. In clinical studies, 1 of 54 (2%) patients who had not previously been treated with ERT, who were then treated with VPRIV, developed antibodies. One additional patient developed antibodies to VPRIV during an extension study. It is unknown if having antibodies to VPRIV is associated with a higher risk of infusion reactions. Patients with an immune response to other enzyme replacement therapies who are switching to VPRIV should continue to be monitored for antibodies to VPRIV.

For additional safety information, please click here for Full Prescribing Information including WARNING for Risk of Anaphylaxis, and discuss with your doctor
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, contact Takeda at 1-877-TAKEDA-7 (1-877-825-3327), or by email at medinfous@takeda.com